Related Experiment Video
Updated: Aug 7, 2026
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1
Elias K Halvas1, Grace M Aldrovandi, Peter Balfe
1Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St., Pittsburgh, PA 15261, and Children's Hospital of Los Angeles, CA, USA.
Abstract:
We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.
More Related Videos
11:19Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
Published on: May 4, 2015
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011